
About Eikonizo
Eikonizo is a Healthcare company based in Cambridge (United States) founded in 2017 by Janice Kranz, Al Schroeder, and William Shaw. Brain-penetrant small molecule therapeutics for neurodegenerative diseases are developed. Eikonizo has raised $2.37 million across 6 funding rounds from investors including Novo Nordisk and HHS. The company has 7 employees. Its chief executive, as recorded, is Janice Kranz. Eikonizo offers products and services including HDAC6 Inhibitors. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is EIKONIZO THERAPEUTICS, INC. Its competitors include T3D Therapeutics, Longeveron and Alzheon; 3 of its 3 listed competitors have raised funding.
Company details
Eikonizo was founded in 2017 in Cambridge, United States, and focuses on the biotechnology sector. Small molecule therapeutics that penetrate the brain are developed to address neurodegenerative diseases. The lead program targets selective histone deacetylase 6 (HDAC6) inhibitors for conditions such as Alzheimers disease and amyotrophic lateral sclerosis. Operations center on advancing these inhibitors through research and development stages.
- Headquarters Cambridge, United States
- Employees 7
- Founders Janice Kranz, Al Schroeder, William Shaw
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website eikonizo.com
- Social LinkedIn X
- Legal Name Eikonizo Therapeutics, Inc.
- Total Equity Funding$2.37M (USD)
in 6 rounds
- InvestorsNovo Nordisk
& 1 more
- Employee Count7
Products & Services of Eikonizo
Eikonizo offers a comprehensive portfolio of products and services, including HDAC6 Inhibitors.
Small molecules that inhibit HDAC6 to improve transport and reduce aggregates in diseases
Funding Insights of Eikonizo
Eikonizo has successfully raised a total of $2.37M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.37M
- Total Rounds 6
- First Round $2M
(Mar 2018)
- Investors Count 2
All 6 funding rounds of Eikonizo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | Seed | β | β | ||
| Sep 2020 | $509,669 | Grant | β | β | |
| Sep 2020 | $299,983 | Grant | β | β | |
| May 2018 | Debt – Conventional | β | β | β | |
| May 2018 | $371,352 | Seed | β | β | β |
| Mar 2018 | $2M | Seed | β | β | β |
2 investors in total: 2 institutional.
Investors in Eikonizo
Eikonizo has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novo Nordisk and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | 1923 | novonordisk.com | Bagsvaerd, Denmark | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Eikonizo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eikonizo
15 people are tracked at Eikonizo (7 in leadership, 6 in board & advisors, 2 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Janice Kranz | Co-Founder & CEO | Leadership |
Al Schroeder | Co-Founder & Director | Leadership |
William Shaw | Co-Founder & Director | Leadership |
Alix Gregory | Head of Operations | Leadership |
Tonya Gilbert | Director, Translational Research | Leadership |
Frederick 'Al' Schroeder | Co-Founder and Director of R&D | Leadership |
Florence Wagner | Director, Medicinal Chemistry | Leadership |
Kevin Kinsella | Director | Board & advisors |
Stuart L. Schreiber | Advisor | Board & advisors |
Brad Rosenblum | Advisor | Board & advisors |
Stacie Weninger | Director | Board & advisors |
Leonard Petrucelli | Advisor | Board & advisors |
Todd Cohen | Advisor | Board & advisors |
Lauren Evans | Senior Scientist | Team |
Rebecca James (she/her), Ph.D. | Research Scientist II | Team |
Complete people profiles for Eikonizo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Eikonizo
3 dated milestones of Eikonizo across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Eikonizo is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Seed,.
Competitors of Eikonizo
Eikonizo has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Longeveron and Alzheon.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| t3dtherapeutics.com | 2013 | Durham, United States | $33.02M | Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed. | ||
| longeveron.com | 2014 | Miami, United States | $1.05M | 23 | Cellular therapies for aging-related and life-threatening conditions are developed. | |
| alzheon.com | 2013 | Framingham, United States | $195.25M | Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed. |
Detailed competitors of Eikonizo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Eikonizo (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eikonizo
Complete news archive for Eikonizo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eikonizo
Eikonizo was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Eikonizo is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Janice Kranz is the CEO of Eikonizo, as recorded in our data. They have also founded this company.
Eikonizo is a funded company, having raised a total of $2.37M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Mar 2018.
Eikonizo has 7 employees.
Eikonizo was founded in 2017 in Cambridge, United States, and focuses on the biotechnology sector. Small molecule therapeutics that penetrate the brain are developed to address neurodegenerative diseases. The lead program targets selective histone deacetylase 6 (HDAC6) inhibitors for conditions such as Alzheimers disease and amyotrophic lateral sclerosis. Operations center on advancing these inhibitors through research and development stages.
Eikonizo's top competitors include Alzheon, Longeveron and T3D Therapeutics.
Eikonizo offers HDAC6 Inhibitors.
Eikonizo has 2 investors. Key investors include Novo Nordisk, and HHS.
Eikonizo operates through Eikonizo Therapeutics, Inc..
